Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
California is completely free of drought for the first time in 25 years - 2Journey Travel Objections for Your Next Experience
- 3Step by step instructions to Pick the Right Web-based Degree Program
- 4Brexit's Effect on New York's Ascent as a Main Monetary Center
- 5Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- Pick Your Number one breakfast food
- Online business Stages for Little Retailers
- The most effective method to Pick The Right Speakers
- How did I get my own unique set of fingerprints?
- Southern Californians, your health insurance costs could rise in 2026
- 6 Exemplary Mexican Dishes
- The most effective method to Distinguish the Best Material Organization in Your Space
- Must-See Attractions in Australia
